Given the class-wide thrombocytopenia seen with clinical pan-BET inhibitors, recent efforts have focused on BD-specific inhibitors (12, –14, 20, 22, , , , , , , –30, 35). This evidence concerns the gene DNER and Thrombocytopenia.